News | May 29, 2024
Lilly increases manufacturing investment to US$ 9 billion at newest Indiana site
Largest investment in active pharmaceutical ingredient manufacturing of synthetic medicines in U.S. history
Largest investment in active pharmaceutical ingredient manufacturing of synthetic medicines in U.S. history
Advancing IGC-AD1 Toward Commercialization as a Treatment for Agitation in Alzheimer's
Asahi Kasei will offer to acquire all of the ordinary shares of Calliditas
These abstracts report on the company's three lead drug candidates, including olverembatinib
Profit Before Tax is Rs. 220 crore, registering a commendable 64% growth
ALS is a rare, progressive and fatal neurodegenerative disease, with an average life expectancy of 3 to 5 years from the time of symptom onset
Updated results from the four studies will be presented in Oral Reports or Posters at the ASCO Annual Meeting
The acquisition is immediately accretive and creates a compelling, single-stop, multi-continent partner for biopharma companies
Further strengthens BaseLaunch's global pharma industry partnerships
The combined entity will enable us to better serve the needs of patients, healthcare professionals and our customers around the world
Subscribe To Our Newsletter & Stay Updated
